No common share has been issued under the April 2017 ATM Program in 2018
On April 24, 2018, the Company terminated the New ATM Sales Agreement, effective May 4, 2018.
http://app.quotemedia.com/data/...change+Act&dateFiled=2018-05-07
|
|
No common share has been issued under the April 2017 ATM Program in 2018
On April 24, 2018, the Company terminated the New ATM Sales Agreement, effective May 4, 2018.
http://app.quotemedia.com/data/...change+Act&dateFiled=2018-05-07
In preparation for the planned MACRILEN launch in July, hired 15 of 16 sales representatives; in the process of hiring two regional business directors and four field reimbursement managers.
http://investors.strongbridgebio.com/node/8786/html
Commitments to Aeterna Zentaris GmbH
In January 2018, we acquired the U.S. and Canadian rights to Macrilen (macimorelin) from Aeterna Zentaris GmbH. Under the terms of the License and Assignment Agreement, we paid Aeterna Zentaris GmbH $24 million, and will pay tiered royalties of 15%-18% on net sales as well as an aggregate of $174 million in potential milestones upon achievement of certain product sales targets. Additionally, Aeterna Zentaris will remain responsible for a pediatric development program to support regulatory submission for approval with Strongbridge sharing oversight and paying for 70 percent of the cost of the program, or approximately $4 million over a three-year period as well as $5 million upon the regulatory approval for use in pediatric patients in the U.S. and Canada. We are obligated to purchase certain amounts of product totaling $1.3 million over the next nine months.
http://investors.strongbridgebio.com/node/8791/html
AETERNA ZENTARIS INC., a company formed under the Canada Business Corporations Act (“ Aeterna ”), has established the AETERNA ZENTARIS INC. 2018 LONG-TERM INCENTIVE PLAN, as set forth herein, and as the same may be amended from time to time (the “ Plan ”). The Plan was adopted by the Board of Directors of Aeterna (the “ Board ”) on March 27, 2018 (the “ Effective Date ”).
Purposes of the Plan.
The Plan is designed to:
(a) promote the long-term financial interests and growth of Aeterna and its Subsidiaries (together, the “ Company ”) by attracting and retaining management and other personnel and key service providers with the training, experience and ability to enable them to make a substantial contribution to the success of the Company’s business;
(b) motivate management personnel by means of growth-related incentives to achieve long-range goals; and
(c) further the alignment of interests of Participants with those of the shareholders of Aeterna through opportunities for increased stock or stock-based ownership in Aeterna.
Toward these objectives, the Administrator may grant stock options, stock appreciation rights, stock awards, stock units, performance shares, performance units, and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan
http://secfilings.nasdaq.com/...20INC.&FormType=S-8&View=html
5. Shares Issuable Pursuant to Awards.
(a) Share Pool .
The number of Common Shares issuable pursuant to Awards that may be granted under this Plan (the “ Share Pool ”) shall not exceed eleven point four percent (11.4%) of the total number of issued and outstanding Common Shares at any given time less the number of Common Shares issuable pursuant to stock options granted at such time under the 2016 Stock Option Plan. Subject to Section 5(c), no one Eligible Individual shall hold options (whether under this Plan or under any other Security-Based Compensation Arrangement) to purchase more than five percent (5%) of the number of Common Shares issued and outstanding from time to time.
(b) Source of Shares.
The Common Shares with respect to which Awards may be made under the Plan shall be shares authorized for issuance under Aeterna’s Articles and By-laws but unissued, or issued and reacquired, including without limitation shares purchased in the open market or in private transactions.
(c) Independent Directors .
http://secfilings.nasdaq.com/...20INC.&FormType=S-8&View=html
From April 2013 until August 2017, Mr. Dodd served as President, CEO of Aeterna Zentaris Inc. (NASDAQ: “AEZS”; www.aezsinc.com); he also served as Chairman of the Board from May 2014 until May 2016. He joined the Company following a series of disappointing clinical development programsthat resulted in a Company stock price decrease in excess of 90%. During Mr. Dodd’s tenure at AEZS, a new, commercial-oriented growth strategy was developed, the Company embarked on a comprehensive restructuring, new corporate governance policies were implemented, including a restructuring of the Board of Directors and the Company focused on rapidly transforming into a growth-oriented, commercially based specialty biopharmaceutical company.As a result, Aeterna Zentaris has it’s first New Drug Application (“NDA”) currently under active review by the FDA, with a PDUFA date of December 30, 2017.
http://www.medizoneint.com/investor-relations/...onal-inc-management/
Authorized shares – 600,000,000 Issued and outstanding shares – 141,736,810 and 106,736,810 at March 31, 2018 and December 31, 2017
Seit 2010 - 2018 von 5 auf 0,038$ und noch nicht fertig!
Series C Convertible Preferred Stock
As of March 31, 2018, there are 2,570 shares of our Series C Convertible Preferred Stock (“Series C Preferred Stock”) outstanding. The Series C Preferred Stock may be converted at any time at the option of the holder into shares of our common stock at a conversion price of $0.015per share, or 171,349,733shares
Series D Convertible Preferred Stock
As of March 31, 2018, there are 550 shares of our Series D Convertible Preferred Stock (“Series D Preferred Stock”) outstanding. The Series D Preferred Stock may be converted at any time at the option of the holder into shares of our common stock at a conversion price of $0.015per share, or 36,666,666shares
"Respekt"!!!!!!
https://www.clinicaltrialsregister.eu/ctr-search/...005546-38/results
Die für mich relevanten Fragen sind damit immer noch nicht geklärt.
Vom Paulaner zum Jever! Die 2$ dürften bald kein Thema mehr sein.
AEterna - von der Gaunerklitsche zum profitablen Unternehmen?! Denke das schaffen sie. Es wird zwar noch ein paar Jahre dauern, aber die Zeit hänge ich noch dran. Erst warten wir mal auf ein positives Zeichen der EMA. Das wird nicht mehr lange auf sich warten lassen.
http://seekingalpha.com/news/...crilen-aghd-accepted-review-shares-16
Am 7. März 2017 hat der Pädiatrieausschuss der EMA dem Pediatric Investigation Plan ("PIP") des Unternehmens für Macrilen ™ zugestimmt, eine Voraussetzung für die Einreichung eines Zulassungsantrags für jedes neue Arzneimittel in Europa. Die EMA stimmte auch zu, dass das Unternehmen die Durchführung des PIP verschieben darf, bis es einen MAA für die Verwendung von Macrilen ™ in AGHD eingereicht hat. Der Beginn des EMA-Überprüfungsverfahrens für das MAA wurde jetzt von der EMA am 23. November 2017 bestätigt http://www.zentaris.com/press-releases 27.11.2017
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |